If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
== Legal implications == At common law, in general, a myocardial infarction is a disease but may sometimes be an injury. This can create coverage issues in the administration of no-fault insurance schemes such as workers' compensation. In general, a heart attack is not covered; however, it may be a work-related injury if it results, for example, from unusual emotional stress or unusual exertion. In addition, in some jurisdictions, heart attacks had by persons in particular occupations such as police officers may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person having had an MI may be prevented from participating in activity that puts other people's lives at risk, for example driving a car or flying an airplane.
In 2003, following the Soccer Australia team's failure to qualify for the 2002 FIFA World Cup, allegations of fraud and mismanagement were levelled at Soccer Australia by elements within the Australian press including the ABC. Soccer Australia commissioned an independent inquiry known as the Crawford Report as a result of the Australian government's threat to withdraw funding to the sport. Any political interference would have constituted a breach of FIFA statutes. The findings of the report were critically analysed by the board of Soccer Australia who believed that the recommendations contained therein were not capable of being implemented. The report recommended, among other things, the reconstitution of the organisation with an interim board headed by prominent businessman Frank Lowy. Some three months after Lowy's appointment, Soccer Australia was placed into liquidation and the Australian Soccer Association (ASA) was created and seized control of the premier soccer competitions and teams without encompassing the Crawford Report recommendations and effectively disenfranchised all other organisations and parties with an interest in Soccer Australia. The Australian government provided approximately $15 million to the ASA. On 1 January 2005, ASA renamed itself Football Federation Australia (FFA), aligning with the international usage of the name "football" in preference to "soccer" and, by a more distinct name, distancing itself from the failings of the former Soccer Australia. It coined the phrase "old soccer, new football" to emphasise this.
=== Deficiency === In humans methionine is an essential amino acid; cysteine is conditionally essential and may be synthesized from non-essential serine via sulfur salvaged from methionine. Sulfur deficiency is uncommon due to the ubiquity of cysteine and methionine in food. Isolated sulfite oxidase deficiency is a rare, fatal genetic disease caused by mutations to sulfite oxidase, which is needed to metabolize sulfites to sulfates.
Canada received 226 of the diverted flights and launched Operation Yellow Ribbon to deal with the large numbers of grounded planes and stranded passengers. The 9/11 attacks had immediate effects on the American people. Police and rescue workers from around the country traveled to New York City to help recover bodies from the remnants of the Twin Towers. More than 3,000 children lost a parent in the attacks. Blood donations across the U.S. surged in the weeks after 9/11.
A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence into the cells of an organism as a mechanism to induce an immune response. DNA vaccines work by injecting genetically engineered plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, so the cells directly produce the antigen, thus causing a protective immunological response. DNA vaccines have theoretical advantages over conventional vaccines, including the "ability to induce a wider range of types of immune response". Several DNA vaccines have been tested for veterinary use. In some cases, protection from disease in animals has been obtained, in others not. Research is ongoing over the approach for viral, bacterial and parasitic diseases in humans, as well as for cancers. In August 2021, Indian authorities gave emergency approval to ZyCoV-D. Developed by Cadila Healthcare, it is the first DNA vaccine approved for humans.
Sources: en.wikipedia.org
=== Hydrogel cross-linked with polyacrylamide === Marketed as Bulkamid, this material is a synthetic non-particulate hydrogel composed of water and cross-linked polyacrylamide (2.5%). The size of the molecules is large which makes it resistant to migration. Since it is a non particulate homogeneous hydrogel, it is thought to retain elasticity and does not lead to hard tissue fibrosis or cause other significant reaction in the surrounding tissues. It is non-resorbable and non allergenic. In plastic surgery it is marketed as Aquamid. In one publication where it was used for FI, intersphincteric injection site was used via the intersphincteric route. This material has not achieved widespread use.
The integument of Sinosauropteryx was closely compared to less controversial evidence of collagen fibers preserved in the ichthyosaur Stenopterygius. Although the collagen hypothesis claimed that the central shafts (rachises) of purported theropod feathers were actually misidentified examples of shaft-like collagen fibers, higher quality imagery showed that these similarities were artificial. The supposed shafts in ichthyosaur collagen were actually scratch marks, cracks, and crevasses created during preparation of one of the ichthyosaur specimens. On the other hand, the shafts in the Sinosauropteryx specimens were legitimate examples of fossilized structures. The collagen hypothesis also claims that Sinosauropteryx integument includes beaded structures similar to structures occasionally found in decaying collagen of modern sea mammals. However, this claim was also unsupported, with Smithwick et al. finding no evidence of the beaded structures which collagen hypothesis proponents identified on the specimens. The study proposes that some areas of the fossil preserved in three dimensions cast shadows which would have resembled beaded structures in low quality photographs. Other examples of purported collagen fibers in the tail area were revealed to be scratches, similar to those on the rest of the specimen. An area of the bone with an irregular surface was considered evidence that some collagen fibers were less decayed than others.
== Personal life == Shaffer lives in Acton, California, and has type four osteogenesis imperfecta, a condition involving a defect in collagen that causes fragile bones and short stature. He is 4 ft 8 in (142 cm) tall. Shaffer is a Christian.
==== Viruses ==== Viral infections as well as endogenized viruses are the subject of ongoing research as factors in autoimmunity. In the case of multiple sclerosis. a large prospective study of US military personnel found that Epstein–Barr virus (EBV) infection precedes onset and raises subsequent risk roughly 32-fold, and later work suggests that whether infection goes on to cause disease depends on inherited differences in how well NK cells and EBV-specific T cells clear the autoreactive cells it produces, combined with differences between EBV strains in their ability to evade that response. A second route to viral autoimmunity may involve endogenous viral elements, more commonly HERVs, which are remnants of ancient viruses that underwent endogenization and became fixed in the human genome. Sporadic reactivation of HERV-W elements, or an alteration in HERV expression has been associated with autoimmunity in systemic lupus erythematosus. and HERV reactivation has been proposed, more speculatively, as a contributor to rheumatoid arthritis through molecular mimicry. Reviews caution, however, that an actual causal role for HERVs in autoimmune disease remains unclear.
Sources: en.wikipedia.org
== History == The Inca were freeze drying potatoes into chuño since the 13th century. The process involved multiple cycles of exposing potatoes to below freezing temperatures on mountain peaks in the Andes during the evening, and squeezing water out and drying them in the sunlight during the day. The Inca people also used the unique climate of the Altiplano to freeze dry meat. The Japanese koya-dofu, freeze-dried tofu, dates to the mid-1500s in Nagano and the 1600s on Mount Koya. These methods are similar but not technically equivalent to the modern process of freeze-drying which requires access to both refrigeration and vacuum systems. Modern freeze drying began as early as 1890 by Richard Altmann who devised a method to freeze dry tissues (either plant or animal), but went virtually unnoticed until the 1930s. In 1909, L. F. Shackell independently created the vacuum chamber by using an electrical pump. No further freeze drying information was documented until Tival in 1927 and Elser in 1934 had patented freeze drying systems with improvements to freezing and condenser steps. A significant turning point for freeze drying occurred during World War II when blood plasma and penicillin were needed to treat the wounded in the field. Because of the lack of refrigerated transport, many serum supplies spoiled before reaching their recipients. The freeze-drying process was developed as a commercial technique that enabled blood plasma and penicillin to be rendered chemically stable and viable without refrigeration.
Liu Wenhui was born to a farming and landowning family in 1895 in Dayi County, Sichuan, as the youngest of six brothers. His parents, Liu Gongzan and Lady Gao, were described by a later biography as having a harmonious marriage. The Liu family had originally come from Huizhou in Anhui, but they had moved to Sichuan early in the Qing era. At the time of Wenhui's birth, Liu Gongzan owned a relatively large plot of one qing of land, which Liu's biography states he worked himself. Liu Wenhui's relatives included his older brother Liu Wencai, who became a major landlord in Dayi County, and his older nephew, Liu Xiang. Liu Gongzan reportedly wanted his youngest son to enlist in the military. Liu Wenhui received his early education at a traditional school in his hometown of Anren, where he studied the Confucian classics under a local teacher. His eldest brother, Liu Wenyuan, later took over his instruction, focusing on classical literature and composition. At age 13, Liu enrolled in the Sichuan Army Elementary School in Chengdu in 1908, part of the Qing New Army training system. He graduated in 1911 and entered the Xi'an Army Middle School, but his studies were interrupted by the Xinhai Revolution, and he returned to Sichuan. At the time, the province was also in the throes of revolutionary upheaval; Zhao Erfeng, the Qing Viceroy of Sichuan, had just been executed by Yin Changheng. Yin, a Tongmenghui member, had served as the president of the Sichuan Army Elementary School.
=== Sponsor === Throughout the clinical trial, the sponsor is responsible for accurately informing the local site investigators of the true historical safety record of the drug, device or other medical treatments to be tested, and of any potential interactions of the study treatment(s) with already approved treatments. This allows the local investigators to make an informed judgment on whether to participate in the study or not. The sponsor is also responsible for monitoring the results of the study as they come in from the various sites as the trial proceeds. In larger clinical trials, a sponsor will use the services of a data monitoring committee (DMC, known in the US as a data safety monitoring board). This independent group of clinicians and statisticians meets periodically to review the unblinded data the sponsor has received so far. The DMC has the power to recommend termination of the study based on their review, for example if the study treatment is causing more deaths than the standard treatment, or seems to be causing unexpected and study-related serious adverse events. The sponsor is responsible for collecting adverse event reports from all site investigators in the study, and for informing all the investigators of the sponsor's judgment as to whether these adverse events were related or not related to the study treatment.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.